<DOC>
	<DOCNO>NCT02571569</DOCNO>
	<brief_summary>Investigate safety , tolerability pharmacokinetics BAY 1093884 Intravenous ( IV ) subcutaneous ( SC ) administration increase single dos .</brief_summary>
	<brief_title>A Single Escalating Dose Study BAY 1093884 Subjects With Severe Hemophilia Types A B , With Without Inhibitors</brief_title>
	<detailed_description />
	<mesh_term>Hemophilia A</mesh_term>
	<mesh_term>Hemophilia B</mesh_term>
	<criteria>Males severe congenital Hemophilia A B define &lt; 1 % FVIII Factor IX ( FIX ) concentration measurement time screen reliable prior documentation For subject Cohorts IIV , ISC1 ISC2 ; If history inhibitor evident , inhibitor titer ≥5 Bethesda Units ( BU ) screen prior screening time medical record . Age : 18 65 year age screen Body mass index ( BMI ) : 18 29.9 kg/m² Subjects know bleed disorder ( von Willebrand factor [ vWF ] deficiency , FXI deficiency , platelet disorder , know acquire inherited thrombophilia etc . ) congenital Hemophilia A B without inhibitor History angina pectoris treatment angina pectoris History coronary and/or peripheral atherosclerotic disease , congestive heart failure , disseminate intravascular coagulopathy , stage 2 hypertension define systolic blood pressure ( SBP ) ≥160 mmHg diastolic blood pressure ( DBP ) ≥100 mmHg even control History thrombophlebitis , venous / arterial thromboembolic disease ( particularly deep vein thrombosis , pulmonary embolism , stroke , myocardial infarction , cerebrovascular accident , ischemic heart disease , transient ischemic attack ) Known suspect hypersensitivity immune system , history anaphylactic reaction , know ( clinically relevant ) allergy , nonallergic drug reaction , multiple drug allergy</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>